A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 9
- Registration Number
- NCT05100628
- Locations
- 🇺🇸
Site name Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic Florida - Oncology, Jacksonville, Florida, United States
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
- Conditions
- Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
- Interventions
- Radiation: EBRT
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 21
- Registration Number
- NCT04957290
- Locations
- 🇺🇸
The University of Texas - MD Anderson Cancer Center - Genitourinary (GU) Cancer Center, Houston, Texas, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 41
- Registration Number
- NCT04555213
- Locations
- 🇲🇩
Institute of Emergency Medicine, Chisinau, Moldova, Republic of
A Study of Safety and Tolerability of NOX66 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Noxopharm Limited
- Registration Number
- NCT03780465
- Locations
- 🇦🇺
Nucleus Network Ltd, Melbourne, Victoria, Australia
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 26
- Registration Number
- NCT03307629
- Locations
- 🇦🇺
Genesis Cancer Care Mater Hospital, Sydney, New South Wales, Australia
🇦🇺Central West Cancer Care Centre - Orange Health Service, Orange, New South Wales, Australia
🇦🇺Genesis Cancer Care - Newcastle, Newcastle, New South Wales, Australia
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 19
- Registration Number
- NCT02941523
- Locations
- 🇬🇪
Academician Z.Tskhakaia West Georgia National Center of Interventional Medicine" LTD/ Oncology Unit- JSC "EVEX Medical Corporation" group member, Kutaisi, Georgia
🇬🇪LTD, Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia
🇬🇪Tbilisi State Medical University's First University Clinic, Department Of Oncology, Tbilisi, Georgia